- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01204541
A Single-Center Pilot Study to Assess Macular Function
February 13, 2012 updated by: ORA, Inc.
This study seeks to evaluate a novel endpoint for future dry AMD clinical trials.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
24
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Andover, Massachusetts, United States, 01810
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Three groups of subjects will be enrolled:
- Normal healthy subjects aged 20-29 years
- Normal healthy subjects aged 60-90 years
- Subjects with early dry AMD
Description
Inclusion Criteria:
- Subjects in good health aged 20-29 or 60-90 years (normal cohorts)
- Subjects with early non-exudative age-related macular degeneration (AMD cohort)
Exclusion Criteria:
- Enrollment in a investigational drug or device study and have used an investigational drug or device within 7 days of enrollment into this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
AMD
|
|
Young normals
|
|
Older normals
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
September 16, 2010
First Submitted That Met QC Criteria
September 16, 2010
First Posted (Estimate)
September 17, 2010
Study Record Updates
Last Update Posted (Estimate)
February 14, 2012
Last Update Submitted That Met QC Criteria
February 13, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-120-0013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular DegenerationRussian Federation
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hui PengNot yet recruitingNeovascular Age-related Macular Degeneration(nAMD)
-
Rophibio, Inc.Not yet recruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
Shanghai General Hospital, Shanghai Jiao Tong University...Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-related Macular DegenerationChina
-
Shanghai Refreshgene Technology Co., Ltd.RecruitingNeovascular Age-related Macular DegenerationChina
-
Lupin Ltd.CompletedNeovascular Age-related Macular DegenerationUnited States, India, Poland, Bulgaria, Slovakia, Hungary, Russia